Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Standardized NDA Review Format Includes Gender Analysis

Executive Summary

Gender analysis is a required component of FDA's newly instituted standardized format for NDA reviews, the agency said April 18.

You may also be interested in...



USP Monographs Will Follow International Format For Drug Impurities

A new format for active pharmaceutical ingredient monographs will provide a more consistent approach to identify impurities, U.S. Pharmacopeia VP-Information & Standards Development Eric Sheinin, PhD, said

USP Monographs Will Follow International Format For Drug Impurities

A new format for active pharmaceutical ingredient monographs will provide a more consistent approach to identify impurities, U.S. Pharmacopeia VP-Information & Standards Development Eric Sheinin, PhD, said

Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.

FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel